Clinical trial

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma

NCT01219790

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention external radiotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Acide zoledronic Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-10-01

PhasePHASE1

Conditions

Prostate Adenocarcinomaverified · MONDO: prostate adenocarcinoma

Interventions

external radiotherapyRADIATION

Acide zoledronicDRUG

Sponsors & collaborators

Institut Cancerologie de l'Ouestlead sponsor

Mapped research locations

LyonFrance1 AngersFrance1 Saint-HerblainFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01219790 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.